Abstract:Background: The private versus public contribution to developing new health knowledge and interventions is deeply contentious. Proponents of commercial innovation highlight its role in late-stage clinical trials, regulatory approval, and widespread distribution. Proponents of public innovation point out the role of public institutions in forming the foundational knowledge undergirding downstream innovation. The rapidly evolving COVID-19 situation has brought with it uniquely proactive public involvement to characterize, treat, and prevent this novel health treat. How has this affected the share of research by industry and public institutions, particularly compared to the experience of previous pandemics, Ebola, H1N1 and Zika? Methods: Using Embase, we categorized all publications for COVID-19, Ebola, H1N1 and Zika as having any author identified as affiliated with industry or not. We placed all disease areas on a common timeline of the number of days since the WHO had declared a Public Health Emergency of International Concern with a six-month lookback window. We plotted the number and proportion of publications over time using a smoothing function and plotted a rolling 30-day cumulative sum to illustrate the variability in publication outputs over time. Results: Industry-affiliated articles represented 2% (1,773 articles) of publications over the 14 months observed for COVID-19, 7% (278 articles) over 7.1 years observed for Ebola, 5% (350 articles) over 12.4 years observed for H1N1, and 3% (160 articles) over the 5.7 years observed for Zika. The proportion of industry-affiliated publications built steadily over the time observed, eventually plateauing around 7.5% for Ebola, 5.5% for H1H1, and 3.5% for Zika. In contrast, COVID-19's proportion oscillated from 1.4% to above 2.7% and then declined again to 1.7%. At this point in the pandemic (i.e., 14 months since the PHEIC), the proportion of industry-affiliated articles had been higher for the other three disease areas; for example, the proportion for H1N1 was twice as high. Conclusions: While the industry-affiliated contribution to the biomedical literature for COVID is extraordinary in its absolute number, its proportional share is unprecedentedly low currently. Nevertheless, the world has witnessed one of the most remarkable mobilizations of the biomedical innovation ecosystem in history.

Biomedical Research Goes Viral: Dangers and Opportunities

COVID-19 Research, Public Health, and Biomedical Basis

How do we change our approach to COVID with the changing face of disease?

Rising to the Challenge of COVID-19: Working on SARS-CoV-2 During the Pandemic

Modelling infectious disease to support human health

We need a global framework for promoting safe handling of high consequence pathogens

How scientific research reacts to international public health emergencies: a global analysis of response patterns

Fundamental Shifts in Research, Ethics and Peer Review in the Era of the COVID-19 Pandemic

Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges

From SARS to COVID-19: is Interdisciplinary Research Progressed in Responding to Another Global Pandemic?

Biologically grounded scientific methods: The challenges ahead for combating epidemics

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Meta-research on COVID-19: An overview of the early trends

Has Covid-19 Gone Viral? An Overview of Research by Subject Area

Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses

Global Outbreak Research: Harmony Not Hegemony

Covid-19 pandemic and the unprecedented mobilisation of scholarly efforts prompted by a health crisis: Scientometric comparisons across SARS, MERS and 2019-nCoV literature

The Covid infodemic Competition and the hyping of virus research

Visible Insights of the Invisible Pandemic: A Scientometric, Altmetric and Topic Trend Analysis

Pandemic Preparedness for COVID-19: Research, Healthcare, and Pharmaceutical Perspectives

The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies